홈 카테고리 맞춤형시장조사 국제컨퍼런스 글로벌 파트너 메일링 서비스 회사소개회사소개 Contact Us
English Japaness Chinese
Home > 시장보고서 > 파머슈티컬 > Gastrointestinal Pharmaceuticals: Technologies and Markets
카테고리
파머슈티컬 (4931)
감염질환 (349)
골질환 치료 (38)
당뇨병 (194)
백신 (181)
비만치료/다이어트 (44)
비처방 의약품 (152)
수의학 (17)
신경질환 (174)
신약개발 (1529)
암치료 (941)
약물전달 (185)
의약품 규제환경 (127)
정신질환 (86)
제네릭 의약품 (128)
제약회사분석 (523)
처방약 (165)
시장보고서

Gastrointestinal Pharmaceuticals: Technologies and Markets

리서치사 BCC Research
발행일 2009년 09월 상품코드 100798
페이지 정보 176 pages
가격
US $ 4,850 ￦ 5,778,700 PDF by E-mail (Single User License)
US $ 5,950 ￦ 7,089,400 PDF by E-mail (Business Unit License)
US $ 8,500 ￦ 10,127,700 PDF by E-mail (Enterprise License)


영문목차

Abstract

THIS REPORT:
  • Provides an overview of gastrointestinal disorders in the U.S.
  • Reviews the gastrointestinal system and explains disorders for their risk factors and mortality rates
  • Offers the current market status for gastrointestinal pharmaceuticals and forecasts through 2014
  • Discusses current pharmaceutical treatments, market size and market participants in both the prescription and over-the-counter arenas
  • Covers potential treatments now in research and development
  • Describes the industry in detail, its relationship to the healthcare industry, its participants and future trends
  • Profiles major companies.

SCOPE OF REPORT

This report is designed to be a comprehensive business tool to provide an in-depth look at gastrointestinal disorders. The geographic scope of the report is global with a particular emphasis on the United States. Market data is global. The report provides an overview of the gastrointestinal system; gives a brief explanation of disorders of the gastrointestinal system; cites risk factors, where applicable; cites incidence and mortality; presents current pharmaceutical treatments, market size and market participants in both prescription and OTC arenas; and presents potential treatments in research and development, potential market size, and market participants. This report describes the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future.

Within the market for gastrointestinal pharmaceuticals, categories are divided into two general segments:

  • Prescription gastrointestinal pharmaceuticals
  • Over-the-counter gastrointestinal pharmaceuticals

The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system including the following:

  • Gastrointestinal tract disorders
  • Gastrointestinal tract wall disorders
  • Gastrointestinal motility disorders
  • Gastrointestinal malabsorption disorders
  • Gastrointestinal cancers

Each sub segment is addressed in detail, describing disorders and the diseases, identifying current and potential products on the market, and competitors involved in the market.

REASONS FOR DOING THE STUDY

This BCC study is presented to heighten the awareness of gastrointestinal disorders and identify pharmaceutical preparations and important advancements in the gastrointestinal markets. The study analyzes therapeutics currently on the market as well as potential products and classes of products that are likely to have a significant impact on the future of both the prescription gastrointestinal drug market and the over-the-counter (OTC) gastrointestinal drug market. Manufacturers of gastrointestinal drug products have stepped up the pace of research and development as the engine driving growth in all markets, especially new treatments for Crohn' s disease and irritable bowel syndrome (IBS). Because of the evolving nature of the many areas of gastrointestinal disorders, executives involved in the specific areas within the gastrointestinal drug market must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities within the gastrointestinal marketplace.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC report are based on extensive firsthand interviews with primary executives, product managers, and clinical specialists in the gastrointestinal pharmaceutical arena. Background information was obtained from various government agencies, business and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of gastrointestinal disorders.

Key information from published literature was used to conduct interviews with more than 45 industry participants to validate and obtain expert opinions on current and future trends in the gastrointestinal pharmaceuticals industry. Interviews were the primary basis for development of market size. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.

All market data pertain to the global market with an emphasis on the U.S. market at the manufacturer' s level. Data are expressed in current U.S. dollars. The base year was 2009. Historical data are provided for 2007 and 2008 and forecast data are provided for 2014. Historical, base year and forecast data are provided for each market segment and sub segment. Market shares are provided for each market segment for the 2009 base year.

ANALYST CREDENTIALS

Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for the last 17 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceuticals industry. Ms. Crandall has a BS and MS in psychology and is a retired medical instructor.

Table of Contents

Gastrointestinal Pharmaceuticals: Technologies and Markets

Chapter- 1: INTRODUCTION -- Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter-2: EXECUTIVE SUMMARY

  • EXECUTIVE SUMMARY
  • SUMMARY TABLE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, THROUGH 2014 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014 ($ MILLIONS)

Chapter-3: INDUSTRY OVERVIEW

  • STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL SYSTEM
  • STRUCTURE AND FUNCTION (CONTINUED)
  • INGESTION AND PROPULSION OF FOOD
  • Mouth
  • Pharynx
  • Esophagus
  • DIGESTION AND ABSORPTION
  • Mouth
  • Stomach
  • Small Intestines
  • Physiology of Digestion
  • Physiology of Digestion (Continued)
  • ELIMINATION
  • Large Intestine
  • LIVER, BILIARY TRACT AND PANCREAS
  • LIVER
  • BILIARY TRACT
  • Bilirubin Metabolism
  • PANCREAS
  • GASTROINTESTINAL TRACT DISORDERS
  • DYSPHAGIA
  • Dysphagia (Continued)
  • ESOPHAGEAL AND ABDOMINAL PAIN
  • VOMITING
  • INTESTINAL GAS
  • CONSTIPATION
  • DIARRHEA
    • TABLE 1 CAUSES OF DIARRHEA
  • GASTROINTESTINAL TRACT WALL DISORDERS
  • GASTRITIS
    • TABLE 2 COMMON CAUSES OF GASTRITIS
  • GASTROENTERITIS
  • PEPTIC ULCER DISEASE
  • Peptic Ulcer Disease (Continued)
  • GASTRIC ULCERS
  • DUODENAL ULCERS
  • INFLAMMATORY BOWEL DISEASE
  • ULCERATIVE COLITIS
  • CROHN' S DISEASE
  • ENTEROCOLITIS
  • DIVERTICULAR DISEASE
  • GASTROINTESTINAL TRACT MOTILITY DISORDERS
  • IRRITABLE BOWEL SYNDROME
  • INTESTINAL OBSTRUCTION
  • GASTROINTESTINAL MALABSORPTION DISORDERS
  • CELIAC DISEASE
  • TROPICAL SPRUE
  • CANCERS OF THE GASTROINTESTINAL TRACT
  • ESOPHAGEAL CANCER
  • GASTRIC CANCER
  • LIVER CANCER
  • PANCREATIC CANCER
  • SMALL INTESTINAL CANCER
  • COLONIC POLYPS AND COLON CANCER
  • Colonic Polyps and (Continued)
  • U.S. DEMOGRAPHICS
    • TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS
    • TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS)
    • FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS)
    • FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2009 AND 2014 (%)
  • PILL-SIZED VIDEO CAMERA
  • PILLCAM ESO
  • SMARTPILL
  • RADIO FREQUENCY IDENTIFICATION TECHNOLOGY
  • IPHONE APPLICATION
  • ENTERIC NERVOUS SYSTEM
  • INSURANCE COVERAGE
  • MONOCLONAL ANTIBODIES
  • WYETH IN SUIT WITH STATES
  • GENERIC INFLUENCE
  • BRANDED VS OTC PROTON PUMP INHIBITORS
  • MAIL ORDER TRENDS
  • MAIL ORDER TRENDS (CONTINUED)

Chapter-4: PRESCRIPTION PRODUCT SEGMENTS BY TYPE

  • ANTIDIARRHEALS
  • SYSTEMICALLY ACTING ANTIDIARRHEALS
  • OPIUM PRODUCTS
    • TABLE 5 MARKETED ANTIDIARRHEAL PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 6 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 3 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 7 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES AND MARKET SHARE LEVELS, BY MANUFACTURER, 2009 ($ MILLIONS/%)
    • FIGURE 4 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES, 2009 ($ MILLIONS)
  • ANTIEMETICS
  • LOCALLY ACTING ANTIEMETICS
  • CENTRALLY ACTING ANTIEMETICS
  • ANTIDOPAMINERGICS
  • Antidopaminergics (Continued)
  • ANTICHOLINERGICS
  • MISCELLANEOUS ANTIEMETICS
  • Miscellaneous Antiemetics (Continued)
  • Miscellaneous Antiemetics (Continued)
    • TABLE 8 MARKETED ANTIEMETIC PRODUCTS
    • TABLE 8 (CONTINUED)
  • MARKET SIZE AND GROWTH
    • TABLE 9 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 5 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 10 GLOBAL PRESCRIPTION ANTIEMETIC REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)
    • FIGURE 6 GLOBAL PRESCRIPTION ANTIEMETICS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)
  • GASTROINTESTINAL CANCER TREATMENTS
  • GASTROINTESTINAL CANCER (CONTINUED)
  • GASTROINTESTINAL CANCER (CONTINUED)
    • TABLE 11 MARKETED GASTROINTESTINAL CANCER PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 12 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 7 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 13 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)
    • FIGURE 8 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES, 2009 ($ MILLIONS)
  • H2 INHIBITORS
  • H2 INHIBITORS (CONTINUED)
  • H2 INHIBITORS (CONTINUED)
  • H2 INHIBITORS (CONTINUED)
    • TABLE 14 MARKETED H2 INHIBITORS PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 15 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 9 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 16 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)
    • FIGURE 10 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES, 2009 ($ MILLIONS)
  • LAXATIVES
  • LAXATIVES (CONTINUED)
    • TABLE 17 MARKETED LAXATIVE PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 18 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 11 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 19 GLOBAL PRESCRIPTION LAXATIVE REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)
    • FIGURE 12 GLOBAL PRESCRIPTION LAXATIVE REVENUES, 2009 ($ MILLIONS)
  • PROTON PUMP INHIBITORS
  • PROTON PUMP INHIBITORS (CONTINUED)
  • PROTON PUMP INHIBITORS (CONTINUED)
    • TABLE 20 MARKETED PROTON PUMP INHIBITOR PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 21 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 13 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 22 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)
    • FIGURE 14 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)
  • BOWEL ANTI-INFLAMMATORY
  • BOWEL ANTI-INFLAMMATORY (CONTINUED)
  • BOWEL ANTI-INFLAMMATORY (CONTINUED)
    • TABLE 23 MARKETED BOWEL ANTI-INFLAMMATORY PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 24 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 15 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 25 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)
    • FIGURE 16 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES BY MANUFACTURER, 2009 ($ MILLIONS)
  • OTHER GASTROINTESTINAL PRODUCTS
  • ANTISPASMODICS
    • TABLE 26 MARKETED ANTISPASMODIC PRODUCTS
  • DIGESTANTS
  • GASTRIC ACIDIFIERS
  • PANCREATIC ENZYMES
    • TABLE 27 MARKETED DIGESTANT PRODUCTS
  • EVACUANTS
    • TABLE 28 MARKETED EVACUANTS PRODUCTS
  • MUCOSAL PROTECTANTS
    • TABLE 29 MARKETED MUCOSAL PROTECTANT PRODUCTS
  • PROSTAGLANDINS
    • TABLE 30 MARKETED PROSTAGLANDIN PRODUCTS
  • STIMULANTS
    • TABLE 31 MARKETED STIMULANT PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 32 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 17 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE
  • TOTAL GLOBAL PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH
    • TABLE 33 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, THROUGH 2014 ($ MILLIONS)
    • FIGURE 18 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, 2007-2014 ($ MILLIONS)
  • TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS
    • TABLE 34 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009)
    • FIGURE 19 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, 2009 ESTIMATED (%)

Chapter-5: OTC PRODUCT SEGMENTS BY TYPE

  • ANTACIDS
  • SYSTEMIC ANTACIDS
  • Sodium Bicarbonate
  • NONSYSTEMIC ANTACIDS
  • Calcium Carbonate
  • Aluminum Products
  • Magnesium Products
  • Combination Products
    • TABLE 35 MARKETED OTC ANTACID PRODUCTS
    • TABLE 35 (CONTINUED)
  • MARKET SIZE AND GROWTH
    • TABLE 36 GLOBAL OTC ANTACID MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 20 GLOBAL OTC ANTACID MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 37 GLOBAL OTC ANTACID REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)
    • FIGURE 21 GLOBAL OTC ANTACID MARKET SHARE BY MANUFACTURER, 2009 (%)
  • LOCALLY ACTING ANTIDIARRHEALS
  • ADSORBENTS
  • INTESTINAL FLORA MODIFIERS
    • TABLE 38 MARKETED OTC ANTIDIARRHEAL PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 39 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 22 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 40 GLOBAL OTC ANTIDIARRHEALS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS/%)
    • FIGURE 23 GLOBAL OTC ANTIDIARRHEALS MARKET SHARE BY MANUFACTURER, 2009 (%)
  • H2 INHIBITORS
  • H2 INHIBITORS (CONTINUED)
  • H2 INHIBITORS (CONTINUED)
    • TABLE 41 MARKETED OTC H2 INHIBITORS PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 42 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 24 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 43 GLOBAL OTC H2 INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)
    • FIGURE 25 GLOBAL OTC H2 INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%)
  • PROTON PUMP INHIBITORS
  • OMEPRAZOLE (PRILOSEC, PROCTER & GAMBLE)
    • TABLE 44 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS
  • MARKET SIZE AND GROWTH
    • TABLE 45 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 26 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 46 GLOBAL OTC PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)
    • FIGURE 27 GLOBAL OTC PROTON PUMP INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%)
  • LAXATIVES
    • TABLE 47 MARKETED OTC LAXATIVE PRODUCTS
    • TABLE 47 (CONTINUED)
  • MARKET SIZE AND GROWTH
    • TABLE 48 GLOBAL OTC LAXATIVES MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
    • FIGURE 28 GLOBAL OTC LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS)
  • COMPETITIVE STRUCTURE AND MARKET SHARE
    • TABLE 49 GLOBAL OTC LAXATIVE REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%)
    • FIGURE 29 GLOBAL OTC LAXATIVE MARKET SHARE BY MANUFACTURER, 2009 (%)
  • TOTAL OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH
    • TABLE 50 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, THROUGH 2014 ($ MILLIONS)
    • FIGURE 30 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, 2007-2014 ($ MILLIONS)
  • TOTAL OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS
    • TABLE 51 TOTAL MANUFACTURERS' REVENUES AND MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 ($ MILLIONS/%)
    • FIGURE 31 TOTAL MANUFACTURERS' MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 (%)
  • RESEARCH AND DEVELOPMENT
  • METOSOLV ODT
  • NEXIUM LOW-DOSE ASPIRIN COMBINATION
  • REZONIC
  • SANVAR
  • TAK-390MR (KAPIDEX)
  • ZENPEP
  • AB-1001
  • ALICAFORSEN
  • APF 530
  • CROFELEMER
  • HUMIRA
  • LINACLOTIDE
  • METHYLNALTREXONE (MNTX) (RELSTAR)
  • MLN 0002 (VEDOLIZUMAB)
  • ORBEC
  • PROCHYMAL
  • RENZAPRIDE
  • REMICADE
  • REZULAR
  • RIFAXIMAN (XIFAXAN)
  • SUTENT
  • ALICAFORSEN ENEMA
  • DEXTOFISOPAM
  • EKB-569
  • GTI-2040
  • PUMOSETRAG
  • RDP-58
  • SORAPRAZAN
  • TALNETANT
  • BL-1030
  • BL-1050
    • TABLE 52 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT
    • TABLE 52 (CONTINUED)
    • TABLE 52 (CONTINUED)
    • TABLE 52 (CONTINUED)
    • TABLE 52 (CONTINUED)
    • TABLE 52 (CONTINUED)
    • TABLE 52 (CONTINUED)
  • TOTAL MARKET ANALYSIS
    • TABLE 53 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER MARKET BY CATEGORY, THROUGH 2014 ($ MILLIONS)
    • FIGURE 32 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY CATEGORY, 2007-2014 ($ MILLIONS)

Chapter-6: INDUSTRY PARTICIPANTS BY PRODUCT TYPE

  • TABLE 54 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS' REVENUES AND MARKET SHARE BY TYPE, 2009 ($ MILLIONS/%)
  • FIGURE 33 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS' MARKET SHARE BY TYPE, 2009 (%)
  • COMPANY PROFILES
  • ASTRAZENECA
  • History
  • AXCAN PHARMA, INC.
  • History
  • CENTOCOR, INC.
  • History
  • EISAI, INC.
  • History
  • GENENTECH, INC.
  • History
  • GLAXOSMITHKLINE
  • Glaxosmithkline (Continued)
  • Glaxosmithkline (Continued)
  • History
  • JOHNSON & JOHNSON
  • History
  • MCNEIL CONSUMER HEALTHCARE
  • History
  • MERCK & CO., INC.
  • History
  • NOVARTIS INTERNATIONAL AG
  • History
  • PFIZER, INC.
  • History
  • PROCTER & GAMBLE CO.
  • History
  • ROCHE
  • History
  • SANOFI-AVENTIS
  • History
  • SALIX PHARMACEUTICALS, LTD.
  • History
  • SOLVAY PHARMACEUTICALS
  • History
  • TAKEDA PHARMACEUTICALS NORTH AMERICA
  • History
  • WYETH
  • History

Chapter-7: CONTACT INFORMATION FOR GASTROINTESTINAL MARKET PARTICIPANTS

  • 3M CORP.
  • ABBOTT LABORATORIES
  • ABEILLE PHARMA, INC.
  • ACAMBIS, PLC
  • ACE BIOSCIENCES A/S
  • AGI THERAPEUTICS, INC.
  • ALCHEMIA, LTD.
  • ALIZYME, PLC
  • ALLERGAN, INC.
  • ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
  • ALTANA PHARMA AG
  • ALVINE PHARMACEUTICALS, INC.
  • AMARIN CORP.
  • AMGEN, INC.
  • ANTIGENICS, INC.
  • APOTHECON B.V.
  • AP PHARMA, INC.
  • ARCO PHARMACEUTICALS
  • ASPHELIA PHARMACEUTICALS, INC.
  • ARYX THERAPEUTICS, INC
  • ASTELLAS PHARMA, INC.
  • ASTRAZENECA, PLC
  • AXCAN PHARMA, INC.
  • BERTEK (MYLAN LABORATORIES INC.)
  • BIOBALANCE, INC.
  • BIOGEN IDEC, INC.
  • BIOLINERX, LTD.
  • BRAINTREE LABORATORIES, INC.
  • BRISTOL-MYERS SQUIBB CO.
  • CELLDEX THERAPEUTICS, INC.
  • CENTOCOR ORTHO BIOTECH, INC.
  • CEPHALON, INC.
  • CERIMON PHARMA, INC.
  • CHEMOCENTRYX, INC.
  • CLAVIS PHARMA ASA
  • COSMO PHARMACEUTICALS SPA
  • CYTOKINE PHARMASCIENCES, INC.
  • DEBIOPHARM S.A.
  • DOR BIOPHARMA, INC.
  • EISAI CO., LTD.
  • ELAN CORPORATION, PLC
  • EMD SERONO, INC.
  • ENZO
  • EURAND PHARMACEUTICALS, INC.
  • EVOKE PHARMA
  • FRESENIUS KABI AG
  • GENENTECH, INC.
  • GENZYME GENERAL
  • GLAXOSMITHKLINE, PLC
  • GLAXOSMITHKLINE CONSUMER HEALTHCARE
  • GLENMARK PHARMACEUTICALS, LTD.
  • H3 PHARMA, INC.
  • HELSINN HEALTHCARE
  • HOFFMAN-LAROCHE, LTD. (ROCHE)
  • HYPERION THERAPEUTICS, INC.
  • IMMUCELL CORP.
  • ISIS PHARMACEUTICALS. INC.
  • JANSSEN PHARMACEUTICA PRODUCTS, LP (JOHNSON & JOHNSON)
  • JOHNSON & JOHNSON
  • LORUS THERAPEUTICS, INC.
  • MCNEIL CONSUMER & SPECIALTY PHARMACEUTICALS
  • MEDISCA, INC.
  • MERCK & CO., INC.
  • MONARCH LABS
  • NABI BIOPHARMACEUTICALS
  • NOVARTIS CORP.
  • NPS PHARMACEUTICALS, INC.
  • OTSUKA AMERICA PHARMACEUTICAL, INC.
  • PFIZER, INC.
  • THE PROCTER & GAMBLE CO.
  • PRODIGENE, INC.
  • PROGENICS PHARMACEUTICALS, INC.
  • RAVEN BIOTECHNOLOGIES, INC.
  • RELIANT PHARMACEUTICALS, INC.
  • ROXANE LABORATORIES, INC.
  • SALIX PHARMACEUTICALS, LTD.
  • SANOFI-AVENTIS
  • SANTARUS, INC.
  • SCHERING AG
  • SCHWARZ PHARMA AG
  • SERONO S.A.
  • SHIRE PHARMACEUTICALS GROUP, PLC
  • SOLVAY S.A.
  • SUCAMPO PHARMACEUTICALS, INC.
  • SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC)
  • TAKEDA PHARMACEUTICAL NORTH AMERICA
  • TARGACEPT, INC.
  • THERAVANCE, INC.
  • UCB PHARMA, INC.
  • UNIMED PHARMACEUTICALS, INC.
  • PHARMOS PHARMACEUTICALS, INC.
  • WATSON PHARMACEUTICALS, INC.
  • WYETH (WHITEHALL-ROBINS HEALTHCARE, INC.)
Back to Top